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The 3-year overall survival was 61% (95%CI, 46-74%) in My+B group and 73%
(95%CI, 54-88%) inMy+T group. At three years post transplant, 75%, 48%, and
60% survival rates were observed in younger than 20, 20-40, and older than
40 years age groups, respectively. No notable differences in 3-year overall
survival among those transplanted in CR1 and CR2 (64% and 69%, respec-
tively). Patients with normal/intermediate cytogenetics (n¼44) and those
with bcr/abl+/poor cytogenetics (n¼27) had similar 3-year survival rates:
62% and 70%, respectively. In conclusion, allogeneic transplant is a valid
treatment option for patients with ABiL and should be explored in patients
without signiﬁcant comorbidities. A study in a larger context is planned.
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Introduction: Patients with CLL who relapse after allogeneic
hematopoietic stem cell transplantation (alloHCT) are difﬁ-
cult to treat with chemotherapy due to impaired hemato-
poietic reserve, infections, and concern for graft-versus-host
disease (GVHD). Ibrutinib (Imbruvica) is approved in the
USA for patients with CLL orMCL who have received1 prior
therapy and for patients with CLL with del17p. In preclinical
studies, ibrutinib reversed established chronic GVHD
(cGVHD). We evaluated the safety and efﬁcacy of ibrutinib in
a subset of patients with prior alloHCT.
Methods: Data were collected for R/R patients with prior
alloHCTenrolled in 1 of 4 clinical trials (PCYC-1102, PCYC-1109,
PCYC-1112, and PCYC-1117). PCYC-1112 and PCYC-1117 only
enrolled patients >6 months post-HCT and without GVHD.
Efﬁcacy evaluations included overall response rate (ORR;
iwCLL criteria), duration of response (DOR), progression-free
survival (PFS), and overall survival (OS). Safety evaluations
included adverse events (AEs), including serious AEs (SAEs).
Results: 16 patients from 4 clinical trials had prior alloHCT
(median age, 54.5 y; 16 patients with ECOG performance
status 0 or 1; 10 patients with del17p, 3 with del11q, 12 pa-
tients with 4 prior therapies). Median time since the most
recent HCT was 27 months (range, 8-115). Baseline neu-
tropenia, anemia, and thrombocytopenia were reported in
31%, 25%, and 38%, respectively. Median time on ibrutinib
was 18.1 months (range, 0.4-38.8), with 12 patients being
treated for >12 months. At data cut-off, 11 patients were
continuing treatment. Reasons for discontinuation included
disease progression (n ¼ 2), AEs (n ¼ 2), and consent with-
drawal (n ¼ 1). Investigator-assessed responses included 2
complete responses, 9 partial responses (PRs), and 3 PRswith
lymphocytosis, resulting in a best ORR of 87.5%. Median DOR,
PFS, and OS were not reached at a median follow-up of 23
months. The 24-month PFS and OS rates were 77% and 75%,
respectively. Treatment-emergent grade 3 SAEs were
observed in 11 patients and included infections (n ¼ 6) and
febrile neutropenia, atrial ﬂutter, colitis, perirenal hema-
toma, subdural hematoma, postprocedural hemorrhage, hy-
percalcemia, bone lesion, syncope, hematuria, urinary
retention, and dyspnea (n¼ 1 each; some events reported for
the same patient). The only AE leading to ibrutinib discon-
tinuation was pneumonia (n ¼ 2); both were fatal events.
Two additional deaths occurred on study due to disease
progression at 24 and 28 months.
Conclusion: Ibrutinibwas well tolerated in patients who had
prior alloHCT, with a safety proﬁle similar to that observed in
the overall R/R CLL population. Best ORR (87.5%) is consistent
with results observed in the overall/broader population.
These data support the use of ibrutinib in CLL patients with
prior alloHCT, and its exploration in treatment of cGVHD is
ongoing (NCT 02195869).77
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Acute biphenotypic leukemias (bearing markers of myeloid
and lymphoid origin, ABiL) are rare (2-5% of all acute leuke-
mias) and are considered puzzling both with regard to their
cell of origin aswell as to theoptimal treatment approach. The
diagnostic criteria for ABiL were revised by the World Health
Organization (WHO) in 2008. In the pediatric age group, the
prognosis of ABiL is reported to be intermediate between
acute lymphoblastic and acutemyeloid leukemia. In the adult
age group, ABiL generally has an unfavorable prognosis. As far
as allogeneic transplant for ABiL is concerned, only small se-
ries of cases have been published to date.
In the current study, the CIBMTR database was queried for
patients with ABiL who received an allogeneic transplant
between 1996 and 2013 being younger than 70 years of age
(n¼468). Patients with primary induction failure (n¼19) and
transplanted in relapse (n¼27) were excluded. After detailed
review of pathology, cytogenetic and ﬂow cytometry reports,
of 241 cases submitted as ABiL, those without complete data
to conﬁrm WHO criteria (n¼157) were excluded. Of 84 cases
with complete immunophenotyping data for review, 48 co-
expressed Myeloid and B-lymphoid markers (M+B) and 28
Myeloid and T-lymphoid markers (M+T). The median age of
the patients was 19 years, 56%weremale, themedianWBC at
diagnosis was 17 000, 36% received a bone marrow, 33%
a peripheral blood graft and 31% cord blood stem cells.
The conditioning regimen was myeloablative in 87% and
RIC/NMA in 10% of cases.
Treatment outcomes are shown below:LYMPHOMA/MULTIPLE MYELOMA78
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Introduction: A negative PET scan predicts improved out-
comes of autologous HCT in lymphoid malignancies. How-
ever, the prognostic utility of pre-transplant PET scan status
in predicting outcomes of alloHCT in NHL is unclear. We
examined the impact of pre alloHCT PET scan status on the
outcomes of NHL patients reported to the CIBMTR.
Methods: Adult patients with follicular lymphoma, diffuse
large B-cell lymphoma (DLBCL), mantle cell lymphoma
(MCL) and T- or NK-cell NHL undergoing alloHCT between
2007-12 were eligible. Chemorefractory pts (by CT criteria),
and cases where interval between PET scan and alloHCT was
>3 months were excluded.
Results: Three hundred and thirtysix patients eligible for this
analysis were divided into PET+ve and PET-ve groups, based
on pre alloHCT PET status, as determined by individual
transplant centers. Baseline patients characteristics shown in
Table. Patients in the PET+ve cohort were more heavily
pretreated, and more frequently had extranodal disease,
marrow involvement and bulky disease. The non-relapse
mortality (NRM), relapse/progression, progression free
survival (PFS) and overall survival (OS) of PET-ve vs. PET+ve
groups at 3years were 27% vs.18% (p¼0.05), 27% vs. 38%
(p¼0.02), 47% vs. 44% (p¼0.66) and 59% vs. 58% (p¼0.81),
respectively. On multivariate analysis, PET+ve status was
associated with a higher risk of relapse/progression (RR
1.76; 95%CI 1.19-2.6; p¼0.004), but was not predictive of
inferior OS (RR 1.29; 95%CI 0.92-1.8; p¼0.13), PFS (RR 1.28;
95%CI 0.95-1.72; p¼0.09) or NRM (RR 0.79 95%CI 0.50-1.24;
p¼0.31). PET status had no impact on incidence of grade II-





Median age, range 54 (19-71) 55 (18-70)
KPS ‡90% 123 (72) 105 (64)
Diagnosis
Follicular NHL 41 (24) 63 (38)
DLBCL 40 (23) 45 (27)
MCL 41 (24) 28 (17)
T/NK-cell NHL 49 (29) 29 (18)
Response with CT @HCT
CR 141 (82) 13 (8)
PR 30 (18) 152 (92)
‡ 3 chemotherapy lines preHCT 88 (57) 106 (70)
Extranodal disease at HCT 20 (12) 58 (35)
Bone marrow involved at HCT 8 (5) 22 (13)
Interval from diagnosis to HCT, months 27 (3-208) 27 (4-352)
Bulky disease 1 (1) 16 (10)
Interval between PET & HCT, months 1 (0.2-2.8) 1 (0.07-2.8)
Prior autoHCT 40 (23) 29 (18)
Donor type
Sibling 62 (36) 60 (36)
Adult unrelated donor 83 (49) 78 (48)
Umbilical cord blood 26 (15) 27 (16)
Conditioning
Myeloablative 47 (27) 43 (26)
RIC 69 (40) 67 (41)
NMA 55 (32) 55 (33)
Median FU, months 49 48Conclusions: A positive pre-alloHCT PET scan in otherwise
chemosensitive NHL patients is associated with a modestly
increased risk of relapse/progression, but is not predictive of
inferior OS and PFS. The results of PET imagingmay direct the
early post-transplant interventions to prevent relapse,
however positive PET should not preclude alloHCT.79
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Introduction: While DCBT is an alternative therapy for pa-
tients (pts) with high-risk lymphomas its efﬁcacy is not
established.
Methods: We analyzed overall survival (OS) and progres-
sion-free survival (PFS) after 4-6/6 HLA-matched DCBT in
adults with B-cell NHL or HL transplanted 2/2006-5/2013.
Results: Pt characteristics and outcomes by diagnosis are
shown (Table). 47 pts (median 46 years, range 20-70) had a
median of 4 prior regimens (range 1-13), 47% had a prior
autologous transplant. The median HCT-CI score was 2 (range
0-6). 60% were in CR. Conditioning was reduced intensity (RI)
in 16 (8 Cy/Flu/Thio/TBI400, 8 Mel/Flu) or non-myeloablative
(NMA, Cy/Flu/TBI200) in 31. CB grafts had a median TNC
dose x 107/kg of 2.7 and 1.9, and a median 5/8 (range 1-7)
donor-recipient HLA-allele match. 98% engrafted (95%CI:77-
99, median 22 and 10 days after RI and NMA conditioning,
respectively). Day 100 grade II-IV acute GVHD (20 grade II, 7
grade III, 1 grade IV) and 1-year chronic GVHD were 61% (95%
CI:45-74) and 17% (95%CI:8-29), respectively. Day 180
transplant-related mortality (TRM) was 17% (95%CI:8-29) and
3-year disease progression was 22% (95%CI:11-34, median 3.4
months, range 2.8-58.0). With a median 60-month (range 15-
101) follow-up, 3-year OS and PFS are 56% (95%CI:44-73) and
44% (95%CI:31-61), respectively (Figure). 7 pts died of
progressive disease whereas 16 had TRM. Best PFS was seen in
follicular NHL (3-year PFS 62%) & HL (3-year PFS 47%) whereas
pts with diffuse large B-cell lymphoma did poorly. There were
no differences in 3-year PFS according to age, HCT-CI, number
of prior regimens or prior autologous transplant, and 28 CR pts
had a 42% 3-year PFS compared to 46% in 19 non-CR pts, p ¼
0.57. Four of 11 pts who relapsed survive (range 29-81
months) after chemotherapy (n ¼ 3) or CB-derived mobilized
peripheral blood stem cell (PBSC) transplant (n¼ 1).
Conclusions: PFS after DCBT in pts with follicular NHL or HL is
similar to that of adult donor allografts and warrants further
investigation. However, DCBT in other histologies is not as
favorable. TRMmay be inﬂuenced by the extent and intensities
of prior therapy. Strategies to risk adapt therapy, reduce TRM
and prevent disease progression are all required. Finally,
chemotherapy to treat post-CBT relapse and CB-derived PBSC
transplant are potential therapeutic options in selectedpatients.
